Aktie A009290 KWANG DONG PHARMACEUTICAL CO., LTD.
Zu einer Liste hinzufügen
Um diese Funktionalität nutzen zu können, müssen Sie Mitglied sein
EinloggenRegistrieren

Andere Sprachen Kwang Dong Pharmaceutical Co., Ltd.

Aktien

A009290

KR7009290008

A009290

Schlusskurs Korea S.E.
Andere Börsenplätze
 00:00:00 20.05.2024 		% 5 Tage % 1. Jan.
6 810 KRW -1,02 % Intraday Chart für Kwang Dong Pharmaceutical Co., Ltd. +1,34 % -8,34 %
18.03. Kwang Dong Pharmaceutical Co., Ltd. meldet Ergebnis für das am 31. Dezember 2023 endende Geschäftsjahr CI
29.01. Zhaoke Ophthalmology gewährt Kwangdong Pharma die Rechte für den Vertrieb von Augentropfen in Korea MT

Andere Sprachen

Suchen
Ergebnisse ansehen
Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!
100% kostenlose Registrierung
Kwang Dong Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023
Zhaoke Ophthalmology Grants Kwangdong Pharma Rights to Distribute Eye Drop in Korea
Bioleaders Corporation announced that it has received KRW 2 billion in funding from Kwang Dong Pharmaceutical Co., Ltd.
Bioleaders Corporation announced that it expects to receive KRW 2 billion in funding from Kwang Dong Pharmaceutical Co., Ltd.
Kwang Dong Pharmaceutical Co., Ltd. agreed to acquire a 58.73% stake in BL Healthcare Corp. from BL Healthcare Corp. for KRW 30 billion
Kwang Dong Pharmaceutical Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
Kwang Dong Pharmaceutical Co., Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
Tranche Update on Kwang Dong Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on April 11, 2023.
Kwang Dong Pharmaceutical Co., Ltd.'s Equity Buyback announced on April 11, 2023, has closed with 1,000,000 shares, representing 2.43% for KRW 6,228.66 million.
Kwang Dong Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023
Kwang Dong Pharmaceutical Co., Ltd. announces an Equity Buyback for 1,000,000 shares.
Kwang Dong Pharmaceutical Co., Ltd. authorizes a Buyback Plan.
Zhaoke Ophthalmology Grants Kwangdong Pharma Rights to Commercialize Myopia Drug in South Korea
Kwang Dong Pharmaceutical Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022
Kwang Dong Pharmaceutical Co., Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022
Kwang Dong Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022
Kwang Dong Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2021
Kwang Dong Pharmaceutical Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021
Oxford Cancer Biomarkers Ltd announced that it has received funding from Kwang Dong Pharmaceutical Co., Ltd.
Tranche Update on Kwang Dong Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on December 6, 2018.
Keine Ergebnisse zu dieser Suche
Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Filter

Suchen

Datum der Veröffentlichung

Vom

Bis

  1. Börse
  2. Aktien
  3. A009290 Aktie
  4. Nachrichten Kwang Dong Pharmaceutical Co., Ltd.
  5. Andere Sprachen